Market Size of Cyclosporine Drugs Industry
| Study Period | 2021 - 2029 |
| Base Year For Estimation | 2023 |
| Forecast Data Period | 2024 - 2029 |
| CAGR | 4.10 % |
| Fastest Growing Market | Asia Pacific |
| Largest Market | North America |
Major Players
*Disclaimer: Major Players sorted in no particular order |
Cyclosporine Drugs Market Analysis
The cyclosporine drugs market is expected to register a CAGR of 4.1% over the forecast period.
The healthcare system has witnessed enormous challenges as a result of the COVID-19 pandemic. All outpatient treatments were postponed or restricted during the COVID-19 pandemic to reduce the risk of viral transmission as most chronic therapies were regarded as non-urgent. In addition, the anti-inflammatory drug cyclosporine was widely used in the management of COVID-19 infection, which was anticipated to have a sizable effect on the market. However, the clinical trials of cyclosporine for COVID-19 infection were reported to be futile. For instance, in August 2022, Quantum Leap Healthcare Collaborative (QLHC), sponsor of the I-SPY COVID trial, stated that the cyclosporine arm of the study has been terminated for futility. The result was a decrease in the number of people taking cyclosporine to treat their COVID-19 infection, which was anticipated to have unfavorable consequences in the long run.
The growing prevalence of target diseases such as inflammatory and autoimmune diseases, the presence of a strong pipeline, and supportive government legislation for disease awareness are some of the key factors driving the growth of this market. As per the report published by JAMA Network, in May 2022, about 3% of Americans and 125 million individuals globally suffer from psoriasis. Both men and women are equally affected by psoriasis, which affects adults more frequently than kids. Cyclosporine is widely used in the treatment of psoriatic diseases as the drug can provide rapid relief from symptoms. Hence, with the increasing burden of target diseases like rises in psoriasis, the demand for the usage of cyclosporine is expected to drive the market over the study period.
In addition, the development of different formulations for various applications and new approval and launches are expected to propel the growth of the cyclosporine drugs market. For instance, in June 2021, Santen Pharmaceutical Co., Ltd. received approval from United States FDA for its new product Verkazia (Cyclosporine ophthalmic emulsion, 0.1%), for the treatment of vernal keratoconjunctivitis (VKC) in children and adults. Moreover, the need for efficient therapies and competition among new market players is expected to provide growth potential in the field of cyclosporine drugs.
However, a lack of awareness of target diseases in developing regions hampers business growth over the forecast period.
Cyclosporine Drugs Industry Segmentation
As per the scope of the report, cyclosporine is a calcineurin inhibitor known for its immunomodulatory properties that prevent organ transplant rejection and treat various inflammatory and autoimmune conditions. It is isolated from the fungus Beauveria nivea. The Cyclosporine Drugs Market is Segmented by Indication (Transplant Rejection Prophylaxis, Rheumatoid Arthritis, Psoriasis, Autoimmune Myasthenia Gravis, Dry Eye, and Others), Route of Administration (Oral and Parenteral), and Geography (North America, Europe, Asia-Pacific, Middle East and Africa, and South America). The market report also covers the estimated market sizes and trends of 17 countries across major regions, globally. The report offers the value (in USD million) for the above segments.
| By Indication | |
| Transplant Rejection Prophylaxis | |
| Rheumatoid Arthritis | |
| Psoriasis | |
| Autoimmune Myasthenia Gravis | |
| Dry Eye | |
| Others |
| By Route of Administration | |
| Oral | |
| Parenteral |
| Geography | ||||||||
| ||||||||
| ||||||||
| ||||||||
| ||||||||
|
Cyclosporine Drugs Market Size Summary
The cyclosporine drugs market is poised for growth, driven by the increasing prevalence of inflammatory and autoimmune diseases, such as psoriasis and rheumatoid arthritis. The market is supported by a robust pipeline of new formulations and favorable government policies aimed at raising disease awareness. Despite the challenges posed by the COVID-19 pandemic, which temporarily affected outpatient treatments and altered the drug's usage dynamics, the market is expected to benefit from the ongoing demand for effective therapies. The development of new product approvals, such as Santen Pharmaceutical's Verkazia for vernal keratoconjunctivitis, highlights the industry's commitment to innovation and meeting diverse medical needs. However, the market's expansion is somewhat hindered by a lack of awareness in developing regions, which affects the overall adoption of cyclosporine-based treatments.
Regionally, North America is anticipated to hold a significant share of the cyclosporine drugs market, bolstered by the presence of major industry players and a high prevalence of target diseases. The region's growth is further supported by strategic product launches and government initiatives focused on disease prevention and treatment. The competitive landscape of the market is moderately intense, with key players like Novartis AG, Sun Pharmaceutical Industries Ltd., and AbbVie Inc. actively engaging in regional expansions and new product developments to maintain their market positions. The market's dynamics are characterized by a blend of global and local players, all vying to leverage the growing demand for cyclosporine in managing chronic conditions.
Cyclosporine Drugs Market Size - Table of Contents
-
1. MARKET DYNAMICS
-
1.1 Market Overview
-
1.2 Market Drivers
-
1.2.1 Growing Prevalence of Target Disease
-
1.2.2 Increase in Potential Clinical Pipeline Candidates
-
1.2.3 Well-Defined Regulatory Guidelines
-
-
1.3 Market Restraints
-
1.3.1 Lack of Awareness of Target Disease In Developing Regions
-
-
1.4 Porter's Five Force Analysis
-
1.4.1 Threat of New Entrants
-
1.4.2 Bargaining Power of Buyers/Consumers
-
1.4.3 Bargaining Power of Suppliers
-
1.4.4 Threat of Substitute Products
-
1.4.5 Intensity of Competitive Rivalry
-
-
-
2. MARKET SEGMENTATION (Market Size by Value - in USD Millions)
-
2.1 By Indication
-
2.1.1 Transplant Rejection Prophylaxis
-
2.1.2 Rheumatoid Arthritis
-
2.1.3 Psoriasis
-
2.1.4 Autoimmune Myasthenia Gravis
-
2.1.5 Dry Eye
-
2.1.6 Others
-
-
2.2 By Route of Administration
-
2.2.1 Oral
-
2.2.2 Parenteral
-
-
2.3 Geography
-
2.3.1 North America
-
2.3.1.1 United States
-
2.3.1.2 Canada
-
2.3.1.3 Mexico
-
-
2.3.2 Europe
-
2.3.2.1 Germany
-
2.3.2.2 United Kingdom
-
2.3.2.3 France
-
2.3.2.4 Italy
-
2.3.2.5 Spain
-
2.3.2.6 Rest of Europe
-
-
2.3.3 Asia-Pacific
-
2.3.3.1 China
-
2.3.3.2 Japan
-
2.3.3.3 India
-
2.3.3.4 Australia
-
2.3.3.5 South Korea
-
2.3.3.6 Rest of Asia-Pacific
-
-
2.3.4 Middle East and Africa
-
2.3.4.1 GCC
-
2.3.4.2 South Africa
-
2.3.4.3 Rest of Middle East and Africa
-
-
2.3.5 South America
-
2.3.5.1 Brazil
-
2.3.5.2 Argentina
-
2.3.5.3 Rest of South America
-
-
-
Cyclosporine Drugs Market Size FAQs
What is the current Cyclosporine Drugs Market size?
The Cyclosporine Drugs Market is projected to register a CAGR of 4.10% during the forecast period (2024-2029)
Who are the key players in Cyclosporine Drugs Market?
AbbVie Inc., Novartis AG, Sun Pharmaceutical Industries Ltd., Teva Pharmaceutical Industries Ltd. and Santen Pharmaceutical Co., Ltd. are the major companies operating in the Cyclosporine Drugs Market.
